Share this article

print logo

Curbing Medicare without vouchers

About 10 years ago, a new radiation treatment for prostate cancer came on line. A single course of "intensity-modulated radiation therapy" cost Medicare about $42,000. The older radiation therapy cost $10,000. Hospitals bought the new machines and stopped using the traditional method. This tacked another $1.5 billion per year to Medicare spending on prostate cancer alone.

Did the fancy new machines do a better job than the old ones? Medicare did not inquire. It just paid. Amazing.

A new McClatchy/Marist poll has 80 percent of Americans opposing cuts in Medicare and Medicaid spending to reduce deficits. Well, 80 percent of Americans don't quite understand Medicare's reimbursement system and how crazy it is.

Forget the Republican plan to squeeze Medicare spending by moving to a voucher system. First, look at the existing setup. For most any treatment deemed "reasonable and necessary," Medicare pays the cost plus some profit. This has turned the program into a brainless check-writing machine.

An article in Health Affairs used the prostate cancer example to show the ludicrous way Medicare pays for things. "Coverage is determined without any requirement for evidence demonstrating that the service in question is equally or more effective than other available options," wrote Steven Pearson, president of the Institute for Technology Assessment in Boston, and Peter Bach, a critical-care physician at Memorial Sloan-Kettering Cancer Center in New York.

Enter "comparative effectiveness research." (I suggest "best for less" as a catchier name.) Comparative effectiveness research studies different treatments for the same condition and identifies those that do the job with the fewest side effects. Medical economists generally agree that our system groans with pricy treatments that provide outcomes no better -- and sometimes worse -- than less-expensive alternatives.

Opponents of this research expressed concern that it would discourage medical innovation. Their unstated worry was that taxpayers would become resistant to sending big checks to equipment makers and other medical providers for bells, whistles and exotic names that add nothing to the quality of care.

Pearson and Bach have come up with an intriguing way to use comparative effectiveness research without stifling the development of improved technology. They would use this research to have Medicare pay the same thing for services that provide equivalent results. But it would reimburse new technologies at the higher rates for, say, three years. If they prove to be superior, then Medicare continues to pay more for them.

What the 80 percent of Americans who oppose spending cuts on the government health plans really want is the assurance that they can get state-of-the-art medical care when they need it. Responsible leaders must impress upon them that enormous savings can be found in Medicare without reducing quality one iota.

There's no need for a radical voucher plan that saves money by sending the elderly to private insurers, then curbing payments to the insurers. The government can continue picking up the bills if Medicare starts considering value received for the checks it writes.

Patients would be happy. Taxpayers would be happy. Some vested interests would not be happy, and they have lots to spend on scaring the public. The question at the end of the day is: Who matters more to our politicians?

There are no comments - be the first to comment